AHR and breast carcinoma: Studies have found that in breast cancer cells, the AhR agonist Aminoflavone pro-drug (AFP464) can inhibit the formation of breast tumor spheres and suppress TIC growth by inhibiting ITGA6 expression in breast cancer (Brantley et al., 2016).